Clinical Research Directory

Inclusion Criteria: * Age ≥18 years; * Patients with coronary artery disease who indicate IVUS-guided drug-eluting stent implantation; * Moderate-to-severe calcified lesions on coronary angiography; * Target lesion is a de novo lesion in a native vessel that has not received any prior interventional treatment; * Target vessel diameter of 2.5-4.0 mm, with guidewire crossing of the target lesion; * In patients with multiple lesions, only one lesion will be selected as the target lesion in this study. If target and non-target lesions are treated during the same procedure, the target and non-target lesions must be located in different vessel branches; furthermore, the non-target lesion must be treated first, and the target lesion may be treated only after successful revascularization of the non-target lesion without severe angiographic complications; * Provision of written informed consent. Exclusion Criteria: * Life expectancy \<1 year; * Cardiogenic shock or hemodynamic instability; * Left main coronary artery disease; * Chronic total occlusion; * Bifurcation lesions planned for a "two-stent strategy"; * Active bleeding; * Known history of allergy to contrast media or metals; * Patients with a bleeding tendency, contraindications to antiplatelet or anticoagulant therapy, or inability to receive anticoagulation therapy; * New-onset stroke/transient ischemic attack within 6 months; * Pregnant or lactating women; * Left ventricular ejection fraction \<25%, or NYHA functional class IV, or Killip class ≥2; * Non-target vessel revascularization within 30 days before randomization with complications.